ENDRA Life Sciences Reports Third Quarter 2026 Financial Results and Provides Business Update
ENDRA Life Sciences (NDRA) reported a Q3 2026 net loss of $1.5 million on operating expenses of $1.7 million, with no revenue; R&D spend fell to $176,000 from $432,000 a year ago while G&A rose on merger-related professional fees. The company ended the quarter with $1.5 million in unrestricted cash, $3.4 million in restricted cash, and $1.3 million in digital assets.
Key figures
- Rnd q3 2025
- 432113
- Rnd q3 2026
- 176280
- Opex q3 2025
- 1370703
- Opex q3 2026
- 1715163
- Digital assets
- $1.3 million
- Restricted cash
- $3.4 million
- Net loss q3 2025
- 1595959
- Net loss q3 2026
- 1528528
- Unrestricted cash
- $1.5 million
- Cash used in operations q3
- $1.8 million
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.